DDF launches $100 mln fund focused on treating dementia

By Iris Dorbian — 4 months ago

The Dementia Discovery Fund, which focuses on developing new dementia treatments, has raised $100 million. DDF’s backers include UK Government’s Department of Health, Alzheimer’s Research UK, Biogen, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Pfizer and Takeda. SV Life Sciences is managing the fund.


Accelerator Corp raises $51.1 mln for fourth fund

By Iris Dorbian — 2 years ago

Accelerator Corp. said Tuesday that it has raised $51.1 million in the first close of its fourth fund. The pool’s investors include Alexandria Venture Investments, ARCH Venture Partners, WRF Capital, Eli Lilly, Harris & Harris Group, Johnson & Johnson Development Corp., The Partnership Fund for New York City and Pfizer Venture Investments. Based in Seattle and New York City, Accelerator Corp is a biotech investment firm.


VC-backed Solstice Biologics hires new president/CEO and CFO

By Iris Dorbian — 2 years ago

San Diego-based biotech startup Solstice Biologics, which is backed by venBio and Aeris Capital, has hired Dr. Lou Tartaglia as president and CEO. Tartaglia has also been added to the firm’s board of directors. Also, the firm has named John Borgeson as chief financial officer. Previously, Tartaglia worked at Third Rock Ventures where he was a partner while Borgeson was vice president of finance for Pfizer‘s biotherapeutic and bioinnovation center.


Kindler Joins Lux Capital

By Luisa Beltran — 4 years ago

Jeff Kindler, the former Chairman and CEO of Pfizer, has joined Lux Capital as a venture partner. Kindler will help identify new healthcare investment opportunities and work with Lux portfolio companies. PRESS RELEASE Lux Capital, a leading venture capital firm, today announced that former Pfizer Chairman and CEO Jeff Kindler joined the firm as a […]


A Mega $11.85 billion Deal for Pfizer Nutrition

By Angela Sormani — 4 years ago

Pfizer is to divest its nutrition business to Nestlé for $11.85 billion in cash. Pfizer’s Nutrition business recorded revenues of approximately $2.1 billion in 2011, an increase of 15% versus 2010. PRESS RELEASE Pfizer today announced that it has entered into an agreement to divest its Nutrition business to Nestlé for $11.85 billion in cash. […]


VCs Encouraged by Stem Cell Therapies in Clinical Trials, ‘Frenzy of Activity’ Predicted

By Reuters News — 4 years ago

(Reuters) – A rogue surgeon injects stem cells from a fetus into a sick man’s brain. The cells morph and form body parts. When the man dies, the pathologist finds cartilage, skin and bone clumped in his brain.

The scene is not from a horror movie; it happened to Max Truex, a former Olympic runner who suffered from Parkinson’s disease. The case sent a chill through the scientific community when it came to light 15 years ago and typifies some of the hurdles researchers have faced while trying to bring stem cell therapies to the market.

Now, it appears, their efforts are closer than ever to paying off.

Dozens of adult stem cell treatments are moving through clinical trials and showing early success, raising hopes that some could reach the market within five years.

“It will only take a few successes to really change the …